Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | PTGFR | P43088 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24652499 | 1.00 | TBXA2R (0.36) | TBXA2RPTGER1PTGFRPTGER3PTGER4 | |
| SCHEMBL26317166 | 1.00 | TBXA2R (0.36) | TBXA2RPTGER1PTGFRPTGER3PTGER4 | |
| SCHEMBL14137768 | 0.82 | PTGER3 (0.37) | TBXA2RPTGER1PTGFRPTGER3PTGER4 | |
| SCHEMBL13866386 | 0.80 | TBXA2R (0.36) | TBXA2RPTGER1PTGFRPTGER3PTGER4 | |
| SCHEMBL11111695 | 0.80 | PTGER3 (0.39) | TBXA2RPTGER1PTGFRPTGER3PTGER4 | |
| SCHEMBL11111697 | 0.80 | PTGER3 (0.39) | TBXA2RPTGER1PTGFRPTGER3PTGER4 | |
| SCHEMBL11101068 | 0.80 | TBXA2R (0.36) | TBXA2RPTGER1PTGFRPTGER3PTGER4 | |
| SCHEMBL13038126 | 0.80 | TBXA2R (0.36) | TBXA2RPTGER1PTGFRPTGER3PTGER4 | |
| SCHEMBL11101119 | 0.80 | TBXA2R (0.36) | TBXA2RPTGER1PTGFRPTGER3PTGER4 | |
| SCHEMBL11516623 | 0.75 | TBXA2R (0.33) | TBXA2RPTGER1PTGFRPTGER3PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738031-B2 | Compositions and methods for preventing or treating muscle conditions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11738031-B2 | Compositions and methods for preventing or treating muscle conditions | PYGM, TNNC1, MYOF | TBXA2R 222/4885PTGER1 24/4885PTGFR 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.